Navigation Links
Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
Date:3/28/2008

MORRISTOWN, N.J., March 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR(R) and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin SR(R) were US$ 498 million for the 12 months ending December 2007 according to IMS Health data.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban(R) and are indicated as an aid to smoking cessation treatment. Annual sales of brand and generic Zyban(R) were US$ 12 million for the 12 months ending December 2007 according to IMS Health data.

Commenting on the new approvals, Terry Fullem, Vice President of Marketing and Portfolio in the U.S. said:

"These approvals further enhance our strength in the area of modified release products and provide valuable options to our customers and patients."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
2. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
3. Seneca Valley High School Student Receives Science Award From MedImmune
4. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
5. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
7. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
11. Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Volunteers supported by SPIE, the ... industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday to urge ... industry. , This year, National Photonics Initiative (NPI) Congressional Visits Day ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... with NASA to showcase the future of deep space exploration and inspire space ... and Orion spacecraft and includes a guest appearance by former Shuttle Astronaut Don ...
(Date:4/26/2017)... ... April 26, 2017 , ... As the ... among healthcare industry stakeholders, the discussion surrounding the topic will continue at WEDI ... 2017 in Los Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange ...
(Date:4/25/2017)... 25, 2017 Providence ... its novel immune-modulating technology to an undisclosed global pharmaceutical ... Tregitopes, pronounced T·rej·itopes, are a set ... EpiVax CEO Annie De Groot and ... G, an autoimmune disease therapy, Tregitopes are capable ...
Breaking Biology Technology:
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/7/2017)... CITY , March 7, 2017   HireVue ... help top global companies identify the best talent, faster, ... as Chief Sales Officer (CSO) and Diana Kucer ... appointments round out a seasoned executive team poised to drive ... beyond, building on a year of record bookings in ...
Breaking Biology News(10 mins):